Gilead Q3 revenues flat, non-GAAP EPS off 5%; shares down 2% after hours

Gilead Sciences (NASDAQ:GILD) Q3 results:

Revenues: $5,604M (+0.1%); product sales: $5,516M (+1.1%); HIV product sales: $4,202M (+12.7%).

Key product sales: Biktarvy: $1,259M (+226.2%); Genvoya: $978M (-16.8%); Truvada: $721M (-4.8%); Epclusa & generic: $516M (+8.2%); Odefsey: 436 (+3.1%); Descovy: 363 (-10.6%)

Net income: ($1,165M) (-155.6%); non-GAAP net income: $2,224M (-7.4%); EPS: ($0.92) (-157.5%); non-GAAP EPS: $1.75 (-4.9%).

2019 guidance: Product sales: $21,800M – 22,100M from $21,600M – 22,100M.

Shares down 2% after hours.

Previously: Gilead Sciences EPS beats by $0.02, revenue in-line (Oct. 24)

https://seekingalpha.com/news/3509344-gilead-q3-revenues-flat-non-gaap-eps-5-percent-shares-2-percent-hours